Financial Performance - The company's operating revenue for Q1 2023 was ¥157,085,973.09, a decrease of 10.67% compared to ¥175,846,115.52 in the same period last year[4] - Net profit attributable to shareholders was ¥83,695,323.17, down 26.74% from ¥114,247,512.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥49,977,078.41, reflecting a decline of 46.73% from ¥93,809,708.75 in the previous year[4] - Basic earnings per share decreased by 61.44% to ¥0.6478 from ¥1.6801 in the previous year[4] - Total operating revenue for Q1 2023 was ¥157,085,973.09, a decrease of 10.7% from ¥175,846,115.52 in the same period last year[41] - Net profit for Q1 2023 was ¥83,695,323.17, down 26.8% from ¥114,247,512.43 in Q1 2022[42] - Basic earnings per share for Q1 2023 were ¥0.6478, compared to ¥1.6801 in the same period last year[43] - The total comprehensive income for Q1 2023 was ¥81,548,148.47, compared to ¥113,288,428.01 in Q1 2022[43] Cash Flow - The net cash flow from operating activities was ¥33,235,082.48, a significant drop of 51.92% compared to ¥69,121,768.37 in the same quarter last year[4] - The net cash flow from operating activities decreased by 51.92% to ¥33,235,082.48 compared to ¥69,121,768.37 in the previous year, primarily due to increased payments for employee salaries and goods[31] - The net cash flow from investing activities dropped significantly by 114.50% to -¥85,192,213.86 from ¥587,466,728.92 in the previous year, mainly due to cash management and fixed asset purchases[31] - The net cash flow from financing activities improved by 99.20% to -¥5,442,871.92 compared to -¥682,728,089.17 in the previous year, mainly due to cash dividends paid in the previous period[31] - The net cash flow from investing activities was CNY -85.192 million, compared to CNY 587.467 million in the previous year[45] - The net cash flow from financing activities was CNY -5.443 million, compared to CNY -682.728 million in the previous year[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,645,508,110.09, an increase of 1.14% from ¥6,570,390,331.09 at the end of the previous year[4] - The total liabilities amounted to ¥193,877,170.53, a decrease from ¥201,007,464.00 in the previous period[20] - The total assets were reported at ¥6,645,508,110.09, slightly down from ¥6,570,390,331.09 in the previous year[20] - The total equity attributable to shareholders increased to ¥6,451,630,939.56 from ¥6,369,382,867.09 in the previous year[20] - The total current assets were reported at ¥6,023,974,157.98, slightly up from ¥5,922,136,726.91 in the previous year[20] - The company’s long-term investments in equity instruments amounted to ¥186,239,867.00, reflecting a stable investment strategy[20] Research and Development - Research and development expenses increased by 113.30% to ¥23,668,344.76, primarily due to the expansion of the R&D team[13] - Research and development expenses for Q1 2023 were ¥23,668,344.76, significantly higher than ¥11,096,271.31 in Q1 2022, indicating increased investment in innovation[41] Government Support and Other Income - The company received government subsidies amounting to ¥2,256,178.76, which included talent project subsidies and other government support[10] - The company reported a significant increase in other income, which rose by 577.28% to ¥2,588,821.76, mainly due to increased government subsidies[13] Market and Business Strategy - The company is exploring market expansion strategies, although specific details were not disclosed in the financial report[39] - The report indicates a focus on regular business growth despite a decline in overall revenue[47] Dividend Distribution - The company plans to distribute a cash dividend of ¥25,840,000 (including tax), amounting to ¥20.00 per 10 shares, pending shareholder approval[37] Miscellaneous - The company has not undergone an audit for the Q1 2023 report[56] - The cash flow from operating activities was not detailed in the provided content but is critical for assessing overall performance[45] - The company experienced a foreign exchange impact of CNY -2.393 million on cash and cash equivalents[45] - Cash and cash equivalents at the end of the period were CNY 2.289 billion, down from CNY 2.837 billion at the end of the previous year[45]

Product Development and Offerings - In 2022, the company launched approximately 1,000 new products, maintaining a core position as a major supplier of infectious disease research reagents with around 68,000 stock products by the end of the year[2]. - The company has developed a product line that includes thousands of biological reagent products, catering to diverse customer research needs[89]. - The company has developed a product library with over 6,500 protein reagent products and approximately 14,000 antibody reagent products, along with around 47,000 gene products[169]. - The company’s recombinant proteins include over 4,500 human cell-expressed products, meeting customer demands for proteins that closely resemble natural human structures and properties[129]. - The company emphasizes the importance of customized services in the biological reagent market, which is expanding due to increasing personalized demands[68]. Financial Performance - The company's operating revenue for 2022 was ¥574,603,390.32, a decrease of 40.47% compared to ¥965,272,540.65 in 2021[56]. - The net profit attributable to shareholders for 2022 was ¥303,134,958.32, down 57.90% from ¥720,013,671.11 in 2021[56]. - The net profit after deducting non-recurring gains and losses was ¥244,352,925.89, a decline of 59.04% compared to ¥596,583,791.15 in the previous year[56]. - The basic earnings per share for 2022 was ¥2.6614, representing a 79.05% decrease from ¥12.7061 in 2021[56]. - The total assets at the end of 2022 were ¥6,570,390,331.09, a decrease of 4.64% from ¥6,890,235,257.55 at the end of 2021[56]. Market Expansion and Strategy - The company signed a lease with Haines Company in November 2022 to establish a new bioresearch center in Houston, Texas, marking a significant step in its global strategic layout[5]. - The company has established subsidiaries in the US, Europe, and Japan, enhancing local service support capabilities[91]. - The company plans to enhance its market position through mergers and acquisitions to increase market concentration in the biological reagent industry[69]. - The company is focused on expanding its market presence through local teams and subsidiaries in key regions[91]. - The company has expanded its market presence in developed countries, establishing subsidiaries in the US, Germany, and Japan to enhance its global footprint[146]. Research and Development - The company plans to continue enhancing its R&D capabilities and expanding its market presence to ensure long-term sustainable development[4]. - The company has a strong R&D team with 44 PhDs, a 19% increase from the previous year, and over 25% of employees holding master's degrees or higher[146]. - The company's overall R&D investment increased by 49.88% year-on-year, enhancing its core competitiveness[168]. - The company emphasizes strong R&D capabilities and rapid response to market demands, exemplified by completing related protein development in just 6 days during the COVID-19 crisis[115]. - The company aims to leverage AI technology and automation in laboratory research to support new product development and enhance its competitive capabilities[186]. Customer Base and Market Demand - The top five customers accounted for CNY 106.94 million in sales, representing 18.61% of the total annual sales, with the largest customer contributing 7.48%[12]. - The company supports over 7,000 clients globally, including universities, research institutions, and pharmaceutical R&D companies, enhancing its brand reputation in the biological reagent industry[103]. - The demand for customized products and services has increased, prompting the company to strengthen local logistics and customer service teams[90]. - The bioreagent and technical service market is characterized by diverse customer needs and a lack of unified quality standards, which the company aims to address[89]. - The company is actively expanding its service business and improving customer satisfaction, leading to a continuous increase in market share and revenue growth[4]. Operational Challenges and Adjustments - The company's unconventional business related to COVID-19 saw a significant decline of 73.19% year-on-year, prompting a strategic business adjustment[187]. - The fourth quarter net profit was significantly impacted by fluctuations in the financial market, particularly due to changes in the fair value of financial products[59]. - Direct labor costs increased by 66.20% to ¥38,390,531.54, making up 44.62% of total operating costs[194]. - Material costs rose by 16.78% to ¥28,843,653.21, accounting for 33.52% of total operating costs[194]. - The company has established a strict quality assessment and control standard for its biological reagent products, ensuring compliance with various operational procedures[135]. Government Support and Subsidies - The company reported government subsidies of CNY 14.78 million in 2022, a decrease from CNY 67.11 million in 2021[22]. - The company has achieved ISO9001, ISO13485, and CNAS certifications, and its purification workshop has passed GMP compliance certification[191]. - The company has established a comprehensive quality management system certified by ISO9001, ISO13485, and CNAS, ensuring product quality throughout its lifecycle[158].

证券代码：301047 证券简称：义翘神州 公告编号：2023-031 北京义翘神州科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 1 一、召开时间及方式 1、召开时间：2023 年 4 月 28 日（星期五）下午 15:00-17:00 2、召开方式：本次年度业绩说明会将采用网络远程的方式举行，投资者可 在上述时间登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年 度业绩说明会。 二、公司出席人员 公司董事兼总经理兼研发总监张杰先生、董事兼董事会秘书兼财务总监冯涛 先生、独立董事尹师州先生、保荐代表人赵陆胤女士。 三、投资者问题征集方式 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面进行提问。公司 将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与！ 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：- | --- | --- | --- | |--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Financial Performance - The company's gross profit margins from 2018 to the first three quarters of 2021 were 83.89%, 85.39%, 96.88%, and 95.01%, indicating an overall upward trend [4] - The significant increase in gross profit margin in 2020 compared to 2019 was primarily due to a substantial increase in sales, which enhanced the company's overall gross profit margin through economies of scale [4] - The gross profit margin for the first three quarters of 2021 remained stable compared to 2020, with confidence in maintaining a high level in the future [4] Group 2: COVID-19 Response - The company has developed a series of biological reagents related to various mutant strains of the COVID-19 virus, supporting basic research, innovative drug development, vaccines, and diagnostic reagents [5] - Over 700 research articles related to COVID-19 have been published globally using the company's biological reagents [5] - Following the emergence of the new COVID-19 variant B.1.1.529, the company initiated a research project to develop relevant biological reagents to support global scientific efforts against the pandemic [5] Group 3: Investor Relations - The investor relations activity included a teleconference with various fund management companies and investment institutions [1][2][3] - Key participants in the investor relations activity included representatives from Tianhong Fund Management, Guotai Junan Securities, and other notable investment firms [1][2][3]

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表（更正版） 编号：2022-005 | --- | --- | --- | --- | --- | --- | |--------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------- ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：2022-004 | --- | --- | --- | --- | |--------------------|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：- | --- | --- | --- | --- | |--------------------|---------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | ...

Financial Performance - The company's revenue for Q3 2022 was ¥130,983,535.64, a decrease of 26.52% compared to the same period last year[6]. - The net profit attributable to shareholders was ¥83,705,363.76, down 26.39% year-on-year[6]. - The net profit excluding non-recurring gains and losses was ¥41,058,539.50, reflecting a significant decline of 58.31% compared to the previous year[6]. - The company's basic earnings per share were ¥0.6479, down 67.71% year-on-year[6]. - In the first three quarters of 2022, the company achieved operating revenue of 430 million RMB, a year-on-year decrease of 47.07%[27]. - In Q3 2022, the company achieved revenue of 131 million yuan, a year-over-year decrease of 26.52%, but a quarter-over-quarter increase of 6.10%[28]. - Revenue from non-COVID-19 related business was 111 million yuan, showing a year-over-year growth of 18.06% and a quarter-over-quarter growth of 13.20%[28]. - Total operating revenue for the current period is CNY 430,286,790.03, a decrease from CNY 812,948,531.27 in the previous period, representing a decline of approximately 47%[40]. - Net profit for the current period is CNY 275,901,898.54, down from CNY 556,362,582.99 in the previous period, indicating a decrease of approximately 51%[43]. - Operating profit decreased to CNY 322,168,393.07 from CNY 658,413,618.40, reflecting a decline of around 51%[43]. - The basic earnings per share for the current period is CNY 2.5359, compared to CNY 10.5195 in the previous period, a decline of approximately 76%[43]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,511,465,199.82, a decrease of 5.50% from the end of the previous year[6]. - As of September 30, 2022, the company's total assets amounted to 6.51 billion yuan, down from 6.89 billion yuan at the beginning of the year[33]. - The company's cash and cash equivalents were approximately 2.37 billion yuan, a decrease from 2.87 billion yuan at the start of the year[33]. - The total liabilities of the company as of September 30, 2022, were 170.83 million yuan, compared to 137.92 million yuan at the beginning of the year[36]. - The company's total equity attributable to shareholders was approximately 6.34 billion yuan, down from 6.75 billion yuan at the beginning of the year[39]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥169,882,187.35, a decrease of 62.73% compared to the same period last year[14]. - Operating cash inflow totaled ¥502,400,622.79, a decrease of 42.4% from ¥872,847,387.20 in the previous period[47]. - Net cash outflow from operating activities was ¥169,882,187.35, down from ¥455,852,218.88, indicating a significant decline[47]. - Cash inflow from investment activities was ¥10,639,688,833.56, compared to ¥2,545,611,806.61 in the prior period, showing a substantial increase[50]. - Cash outflow from financing activities amounted to ¥693,261,769.57, while the previous period recorded inflow of ¥4,720,050,530.28, indicating a shift in financing strategy[50]. - The ending balance of cash and cash equivalents was ¥2,325,314,658.30, down from ¥4,654,977,849.90, indicating a liquidity contraction[50]. Inventory and Fixed Assets - Inventory increased by 67.27% to ¥41,401,459.95, primarily due to increased raw material reserves[11]. - Fixed assets rose by 75.98% to ¥104,549,193.03, mainly due to the purchase of production and R&D equipment[11]. - The company reported an increase in inventory to approximately 41.40 million yuan, up from 24.75 million yuan at the beginning of the year[33]. Research and Development - The company maintained its position as a mainstream supplier of COVID-19 related biological reagents, leveraging its extensive R&D experience in the field[27]. - The company increased its R&D investment in non-COVID-19 related business, resulting in a 30.52% year-on-year increase in CRO service revenue, totaling 76.81 million RMB[27]. - The company’s strategic focus on enhancing long-term competitiveness through increased R&D investment in non-COVID-19 related business is evident[27]. - Research and development expenses for the current period are CNY 39,332,093.12, up from CNY 32,116,971.18, indicating an increase of approximately 22%[40]. Government Support and Other Income - The company received government subsidies amounting to ¥13,363,773.64 during the reporting period[9]. - Other income increased to CNY 13,924,074.09 from CNY 3,353,594.12, reflecting a growth of about 316%[40]. - The company reported a tax expense of CNY 46,290,442.18, down from CNY 101,551,035.41, indicating a decrease of approximately 54%[43]. Subsidiary Developments - The Suzhou subsidiary has completed renovation acceptance and is currently in the laboratory equipment debugging phase[32]. - The Taizhou subsidiary has completed the main renovation work of the first phase of the laboratory and has begun trial operations[32]. - The company has ongoing projects in Suzhou and Taizhou, indicating a focus on market expansion and new technology development[32].

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[21] - The company reported a total revenue of CNY 299.30 million, a decrease of 52.84% compared to the same period last year[28] - Net profit attributable to shareholders was CNY 192.20 million, down 56.58% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 152.78 million, a decline of 63.75%[28] - Cash flow from operating activities was CNY 115.36 million, representing a decrease of 70.43% compared to the previous year[28] - The company achieved revenue of CNY 1.08 billion from COVID-19 related business, accounting for 36.20% of total revenue, but this was a 76.33% decline year-on-year[40] - Non-COVID-19 related business revenue was CNY 1.91 billion, showing a year-on-year growth of 7.88%[40] - The company's operating revenue for the reporting period was ¥299,303,254.39, a decrease of 52.84% compared to ¥634,698,110.16 in the same period last year, primarily due to a decline in revenue from COVID-19 related products[76] - The company's cash flow from operating activities decreased by 70.43% to ¥115,360,989.28, primarily due to reduced revenue from COVID-19 related business[76] Profitability and Margins - The gross profit margin improved to 60%, up from 55% in the same period last year[21] - The gross profit margin for recombinant proteins was 89.93%, while for antibodies it was 96.13%, indicating strong profitability in these segments despite a significant drop in revenue[80] Research and Development - The company has allocated RMB 100 million for research and development in 2022, a 30% increase compared to the previous year[21] - The company has invested heavily in R&D, maintaining a leading position in the domestic biological reagent industry, and has developed multiple core technology platforms to meet market demands efficiently[63] - The company’s R&D investment increased by 28.32% to ¥23,457,860.61 from ¥18,280,828.79 in the previous year, reflecting a commitment to enhancing its core competitiveness[76] - The company has a high-quality team with 37 PhDs, and nearly one-third of employees hold graduate degrees, enhancing its R&D capabilities[71] Market Expansion and Strategy - The company plans to launch three new products in Q4 2022, focusing on advanced biotechnologies[21] - The company is expanding its market presence in Europe, with a new office opening in Germany by the end of 2022[21] - A strategic acquisition of a biotech firm is in progress, aimed at enhancing R&D capabilities and product offerings[21] - The company has established local teams in both domestic and international markets, with subsidiaries in Taizhou and Suzhou expected to commence operations within the year, supporting rapid growth in cell culture and CRO services[44] - The overseas subsidiaries in Japan have begun operations, while the US and European subsidiaries are enhancing their business teams and expanding market activities to improve customer relationship management and brand influence[44] - The company has expanded its market presence internationally, establishing sales teams in developed countries such as the US, Germany, and Japan, with products sold in over 90 countries[72] Product Development and Quality Control - The company successfully established a production technology platform for full-length multi-pass membrane proteins, filling a gap in its product offerings[43] - The company introduced high-quality GMP-grade cytokine products, enhancing product purity and activity to meet industrial cell therapy demands[43] - The company has developed a comprehensive quality control system to ensure product quality and stability, contributing to a good reputation and expanding its customer base[65] - The company has established a comprehensive quality management system, achieving certifications such as ISO9001 and ISO13485, to ensure product quality throughout its lifecycle[55] Risks and Challenges - The company has identified potential risks related to supply chain disruptions and is implementing measures to mitigate these risks[4] - The company faces risks of revenue decline due to the potential decrease in demand for COVID-19 related products as the pandemic situation stabilizes[105] - The company is at risk of core technology leakage, which could adversely affect its operations and market competitiveness[107] - The competitive landscape in the life sciences and biopharmaceutical sectors is intensifying, necessitating continuous improvement in technology and product quality[110] - Trade tensions, particularly with the U.S., pose a risk to the company's market position and pricing competitiveness[111] Shareholder and Governance - The company held its annual general meeting on March 21, 2022, with an investor participation rate of 75.17%[120] - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[122] - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[121] - The company did not have any significant environmental issues or administrative penalties during the reporting period[127] - The company actively engages in social responsibility initiatives and maintains good communication with stakeholders[135] - The company adheres to relevant laws and regulations to protect the rights of shareholders and employees[130] Financial Position - Cash and cash equivalents at the end of the reporting period amounted to ¥2,842,693,663.49, representing 44.38% of total assets, an increase of 2.69% compared to the previous year[81] - Trading financial assets decreased to ¥3,105,935,138.35, accounting for 48.49% of total assets, a decline of 4.31% from the previous year[81] - Accounts receivable stood at ¥146,727,810.29, which is 2.29% of total assets, showing a slight increase of 0.06% compared to the previous year[81] - Inventory increased to ¥34,917,186.15, representing 0.55% of total assets, up by 0.19% from the previous year[81] - Fixed assets rose to ¥85,021,646.22, accounting for 1.33% of total assets, an increase of 0.47% year-on-year[81] - As of June 30, 2022, the company's total current assets amounted to approximately CNY 6.16 billion, a decrease of about 8.26% from CNY 6.72 billion at the beginning of the year[198] - The company's cash and cash equivalents were CNY 2.84 billion, down from CNY 2.87 billion at the start of the year, indicating a decline of approximately 1.47%[198] - The trading financial assets decreased to CNY 3.10 billion from CNY 3.64 billion, reflecting a reduction of about 14.66%[198] - Accounts receivable stood at CNY 146.73 million, a slight decrease from CNY 153.45 million, representing a decline of approximately 4.4%[198] - Inventory increased significantly to CNY 34.92 million from CNY 24.75 million, marking an increase of about 41.1%[198]